Pangea Laboratory has partnered with Unilabs, a leading European provider of clinical laboratory testing and diagnostic imaging services, to bring the Bladder CARE™ Assay to Switzerland. Under this agreement, the Bladder CARE™ Assay will be covered by insurance, enhancing access for patients. This strategic collaboration aims to streamline cancer diagnostics in Switzerland, with plans for a broader rollout of Bladder CARE™ across Europe. The partnership underscores Pangea Laboratory's commitment to making innovative diagnostic solutions widely accessible globally.

Awarded Breakthrough Device Designation by the FDA, the Bladder CARE™ Assay analyzes DNA methylation biomarkers to detect bladder cancer and upper tract urothelial carcinoma (UTUC) from urine samples, which can be conveniently collected at home. With sensitivity, specificity, and NPV exceeding 93% for both conditions, along with quantitative results, the Bladder CARE™ Assay stands out from other commercially available tests.

"Through this strategic partnership with Pangea Laboratory, Unilabs reinforces its commitment to driving innovation in diagnostics, bringing Bladder CARE™ to Switzerland as a next-generation solution that empowers early detection and advances patient care," said Patrick Bornand, Head of Pathology, Genetics & Oncology at Unilabs Switzerland.

"Pangea Laboratory is committed to delivering non-invasive healthcare solutions that reduce patient burden while delivering highly accurate results. We are happy that the Unilabs team shares our vision, and the belief that Bladder CARE™ sets a new standard in the diagnosis of bladder cancer and UTUC," said Dr. Yap Ching Chew, COO of Pangea Laboratory.